linjc16/ctgov huggingface dataset:
The Secretion of Incretin Hormones in Patients With Polycystic Ovary Syndrome

Study Overview
=================
Brief Summary
-----------------
Polycystic ovary syndrome (PCOS) is an endocrine disease in reproductive women. It is characterized by anovulation and hyperandrogenism. Most patients with PCOS have metabolic abnormalities such as dyslipidemia, insulin resistance and glucose abnormalities. Almost 60-80﹪PCOS patients are obesity which exacerbates IR and hyperandrogenism. Obese PCOS patients tend to be overeating suggests that impaired appetite regulation might be contribute to the pathophysiology of PCOS. Our study is trying to observe difference of incretin between PCOS and normal control to figure out whether change of incretin is involved in the pathophysiology of PCOS.

Official Title
-----------------
The Secretion of Incretin Hormones in Patients With Polycystic Ovary Syndrome

Conditions
-----------------
Polycystic Ovary Syndrome

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: women at reproductive age women with PCOS and women without PCOS Exclusion Criteria: young women who had their menarche less than 3 years women older than 45 years old, Amenorrhea of menopause, hyperglycemia, hyperthyroidism, hypothyroidism, heart failure, lung failure, renal failure, anemia, dystrophy, gonitis

Ages Eligible for Study
-----------------
Minimum Age: 13 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| PCOS cohort<br>Women with PCOS | |
| Control cohort<br>Women without PCOS | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in incretin hormones secretion in PCOS patients. |  | up to 14 months |
Observational Study on the Incidence of NSF in Renal Impaired Patients Following Dotarem Administration

Study Overview
=================
Brief Summary
-----------------
The main purpose of this study is to prospectively estimate the incidence of Nephrogenic Systemic Fibrosis (NSF) in patients with moderate to severe renal impairment after administration of Dotarem®

Detailed Description
-----------------
All patients will be followed up during 2 years after Dotarem® administration to collect data on any suspected NSF or NSF-related symptoms

Official Title
-----------------
Observational Study on the Incidence of NSF in Renal Impaired Patients Following Dotarem Administration

Conditions
-----------------
Renal Insufficiency

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with moderate to severe and end stage renal impairment or dialysis, scheduled for a contrast-enhanced Magnetic Resonance Imaging (MRI) with Dotarem Exclusion Criteria: Patient who has received a Gadolinium Based Contrast Agent (GBCA) within the past 12 months prior to inclusion in this study except if the GBCA received is Dotarem
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of Patients With Moderate to Severe Renal Impairment Who Develop Nephrogenic Systemic Fibrosis (NSF) After Administration of Dotarem |  | All patients were followed up during 2 years after Dotarem administration. |
Mirena Observational Program

Study Overview
=================
Brief Summary
-----------------
Mirena is used for long-term in Kazakhstan, and in our observational program we would like to study patients distribution per indications of Mirena, and also patient compliance within a year after Mirena insertion. For patients with all approved indications for Mirena use: contraception, treatment of menorrhagia and protection from endometrial hyperplasia during estrogen replacement therapy

Official Title
-----------------
Mirena Observational Program

Conditions
-----------------
Contraception, Menorrhagia, Endometrial Hyperplasia, Estrogen Replacement Therapy

Intervention / Treatment
-----------------
* Drug: Levonorgestrel (Mirena, BAY86-5028)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients older than 18 years with previously taken decision of their gynecologist to insert Mirena according to registered indications Exclusion Criteria: All patients with contraindications to Mirena insertion, according to approved prescribing information.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Group 1<br> | Drug: Levonorgestrel (Mirena, BAY86-5028)<br>* Patients older than 18 years with previously taken decision of their gynecologist to insert Mirena according to registered indications<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Patient distribution per indication |  | 12 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Patient compliance |  | 12 months |
Salpingectomy vs Tubal Sterilisation in Low Risk for Ovarian Cancer Women and Its Effect on Ovarian Reserve

Study Overview
=================
Brief Summary
-----------------
Randomised study to investigate if salpingectomies done to women wishing tubal sterilisation has an effect on ovarian reserve.

Conditions
-----------------
Ovarian Cancer

Intervention / Treatment
-----------------
* Procedure: Bilateral Salpingectomy
* Procedure: Tubal sterilization with bipolar energy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Women seeking for tubal sterilisation Exclusion Criteria: women older than 45 family history of ovarian cancer presence of menopausal symptoms irregular cycles Hormone Replacement Therapy or hormone contraceptions the last 3 months history of previous ovarian or uterine surgeries imaging suggesting an ovarian cyst or other adnexal pathology during investigation previous salpingectomy

Ages Eligible for Study
-----------------
Minimum Age: 25 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Tubal Sterilization with bipolar<br>Salpingectomy vs Tubal Sterilisation | Procedure: Tubal sterilization with bipolar energy<br> <br> |
| Active Comparator: Bilateral Salpingectomy<br>Salpingectomy vs Tubal Sterilisation | Procedure: Bilateral Salpingectomy<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Anti-Mullerian hormone (AMH)and Follicle Stimulation Hormone (FSH) |  | 3 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Anti-Mullerian hormone (AMH) |  | 1 year | 
| Operative time |  | Postoperatively | 
| Complications |  | 3 months |
Validation of PINI Score in ICU

Study Overview
=================
Brief Summary
-----------------
Prospective, observational clinical monocentric study in ICU; Relationship between Pronostic Inflammatory and Nutritional Index (PINI) (and biomarkers related to PINI) and mortality, morbidity and nutrition in ICU

Detailed Description
-----------------
Main objective: to evaluate the relationship between PINI score and biomarker related to PINI, and 28 days mortality in ICU Secondary objectives: to evaluate the relationship between PINI score (and biomarkers related to PINI) and morbidity in ICU : SOFA score, duration of ventilation, duration of antibiotherapy, duration of extra renal epuration, length of stay to evaluate the relationship between PINI score (and biomarkers related to PINI) and nutrition in ICU (type of nutrition, calorie content)

Official Title
-----------------
Validation of PINI Score in ICU

Conditions
-----------------
ICU Patients

Intervention / Treatment
-----------------
* Other: non applicable


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Both patient in ICU Exclusion Criteria: minor patient No possibility to calculate PINI score Pregnant woman

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: non applicable|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| PINI Score |  | at day 1 | 
| Biomarkers related to PINI |  | at day 1 | 
| Mortality at 28 days |  | after admission | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Length of stay |  | at day 1 | 
| Duration of ventilation |  | at day 1 | 
| Duration of antibiotherapy |  | at day 1 | 
| Duration of renal replacement therapy |  | at day 1 | 
| Type of nutrition (enteral/parenteral) |  | at day 1 | 
| Calorie content per day |  | at day 1 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Biological evaluation of denutrition, Denutrition, PINI score
Myocardial Injury After Elective Coronary Stenting

Study Overview
=================
Brief Summary
-----------------
This pilot study aims to identify patients at moderate to high risk for peri-procedural (type 4) myocardial infarction or injury after after undergoing an elective coronary intervention (PCI) as measured by high sensitivity troponin T, who might benefit from more potent antiplatelet therapy.

Official Title
-----------------
Identification of Patients at Higher Risk for Myocardial Injury or Type 4a Infarction Following Elective Coronary Artery Stenting

Conditions
-----------------
Coronary Artery Disease

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Stable or unknown coronary artery disease (CAD) Elective coronary intervention Minimum age of 18 Exclusion Criteria: Present acute coronary syndrome (ACS) Age under 18 Pregnancy Any additional invasive intervention with potential myocardial injury Non ACS conditions responsible for elevation of cardiac troponin, such as acute pulmonary artery embolism, myocarditis or tachycardia.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Patients undergoing elective PCI<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Postprocedural myocardial infarction (type 4a) or injury |  | up to 72 hours after procedure | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Percutaneous Coronary Intervention, Cardiac troponin, Antiplatelet therapy
Pancreatic Calcium Handling in Islet Beta Cells in Patients With Type 1 Diabetes Mellitus

Study Overview
=================
Brief Summary
-----------------
Approximately 400,000 people are living with type 1 diabetes mellitus (T1DM) in the United Kingdom: one of the highest rates in the world. It is characterised by autoimmune loss of pancreatic beta cell mass leading to metabolic dysregulation, requiring lifelong insulin therapy. It is now recognised that there are micro-secretors of insulin and that preservation of insulin secretion in these cases is associated with decreased complications. Therefore, recent research has focussed on using immunomodulation to preserve pancreatic beta cell mass. Evaluation of novel therapies for T1DM requires reliable methods to measure beta-cell function, which is unattainable using traditional non-invasive imaging techniques. A new approach is manganese-enhanced magnetic resonance imaging (MEMRI). This proof-of-concept study was designed to investigate whether MEMRI can be used as a measure of beta-cell function in people with T1DM.

Official Title
-----------------
Pancreatic Calcium Handling in Islet Beta Cells in Patients With Type 1 Diabetes Mellitus

Conditions
-----------------
Type 1 Diabetes

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age >18 years No regular medications No known significant medical conditions Exclusion Criteria: Inability to consent Renal failure (eGFR <30 mL/min/1.73 m2) Standard MRI contraindications Pregnancy or breast feeding

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Healthy volunteers<br>Healthy volunteers with no known significant medical conditions | |
| Patients with type 1 diabetes<br>Patients with a diagnosis of type 1 diabetes (with or without detectable C-peptide) | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pancreatic calcium-handling: Rate of change of pancreatic T1 values with manganese-enhanced magnetic resonance imaging |  | 30 minutes after contrast administration |
Helping People to Exercise Regularly

Study Overview
=================
Brief Summary
-----------------
This study tests two different incentive mechanisms to induce members of a particular urban senior center to attend more exercise classes. Coupons for future use are given to participants who attend an exercise class and will be redeemable within either a one week or three month time period, depending on which experimental group the participant is assigned to. Frequency of exercise class attendance at the end of 2 months will be the primary outcome.

Official Title
-----------------
Helping People to Exercise Regularly

Conditions
-----------------
Obesity, Heart Disease

Intervention / Treatment
-----------------
* Behavioral: Coupons for use within the next week
* Behavioral: Coupons for use within the next 3 months


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age 55 years or older Member of the Philadelphia Senior Center Exclusion Criteria: None

Ages Eligible for Study
-----------------
Minimum Age: 55 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Promotion I<br>Three month time horizon | Behavioral: Coupons for use within the next 3 months<br>* Participants who attend an exercise class will receive a coupon to attend an exercise class for free within the next 3 months.<br>|
| Experimental: Promotion II<br>One week time horizon | Behavioral: Coupons for use within the next week<br>* Participants who attend an exercise class will receive a coupon for a free exercise class to be used within the next week.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Frequency of exercise class attendance |  | 2 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Obesity, Heart Disease, Seniors, Elderly, Chronic Disease, Prevention
The Effects of Seasonal Changes in Osteoporosis Treatment

Study Overview
=================
Brief Summary
-----------------
There are few reports concerning to the seasonal variation of osteoporosis treatment. In this study, we plan to compare clinical efficacy and safety by seasons.

Detailed Description
-----------------
Vitamin D insufficiency is common in many countries. Vitamin D insufficiency is associated with osteoporosis and the responses to osteoporosis treatment. 25-hydroxyvitamin D (25OHD) is considered to be the best estimate of body stores of vitamin D and the seasonal variation of 25OHD is well known. But there are few reports concerning to the seasonal variation of osteoporosis treatment. In this study, we plan to compare clinical efficacy and safety by seasons in patients treated by raloxifene.

Official Title
-----------------
The Effects of Seasonal Changes in Osteoporosis Treatment

Conditions
-----------------
Selective Estrogen Receptor Modulator (SERM)

Intervention / Treatment
-----------------
* Drug: Raloxifene


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Postmenopausal women Exclusion Criteria: Patients who could not use SERM

Ages Eligible for Study
-----------------
Minimum Age: 45 Years
Maximum Age: 100 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Raloxifene|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Effects of raloxifene on bone mineral density in postmenopausal osteoporosis. |  | Up to 36 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
SERM, Season, Variation, Vitamin D
Association Between Cancer and Sarcoidosis

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to develop a clinical dataset of sarcoidosis patients with a diagnosis of cancer who are categorized by date of birth, sex, race/ethnicity, clinical information, laboratory and imaging information, time of sarcoidosis onset, cancer type and treatment, time of cancer diagnosis, stage and grade.

Official Title
-----------------
Outcome Study of Sarcoidosis: a New Paraneoplastic Syndrome in Patient With Cancer

Conditions
-----------------
Sarcoidosis, Cancer

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Clinical diagnosis of Sarcoidosis following cancer Granulomatous reaction must be proven by pathology Exclusion Criteria: . Aged younger than 18 years old.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Patients with Sarcoidosis and Cancer<br>These group of patients have a diagnosis of Sarcoidosis and Cancer on the Pathological Report. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pathology Proven Sarcoidosis In Patients with Cancer | Number of Participants With Sarcoidosis Events as Assessed by Positive Granulomatous Reaction in the Biopsies of Lung, Mediastinal Lymph Nodes, or Other Organs After Cancer Diagnosis. | up to 10 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Cancer Cytogenetics and Sarcoidosis | Number of Participants With Sarcoidosis Events as Assessed by Cancer Cytogenetic Profiles of Cancer. | up to 10 years | 
| Treatment Requirement of Sarcoidosis | Number of Participants With Sarcoidosis Events as Assessed by Requirement of Treatment with Steroid or Other Anti-Sarcoid Medications in Patients with Cancer. | up to 10 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
sarcoidosis, cancer, paraneoplastic, treatment, outcome